Innoviva, Inc. (INVA) — closed signal from December 14, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 14, 2026.
Predicted vs. what happened
What happened
Reached 63% of the predicted growth at its peak, without hitting the target.
The thesis — published December 14, 2025
The stock has a clear near-term reason to move up: the FDA approved a new single-dose oral gonorrhea drug and the company plans to start selling it in the second half of 2026. The price recently fell a lot, so a rebound is possible, but trading can be erratic and low volume means buy small and expect quick swings.
Primary drivers
- FDA approval lowers the chance of failure and makes the drug more valuable
- How the company sells the drug matters: partner or go alone affects earnings
- Shares dropped a lot so a bounce is more likely than usual
- Mix of business health and price action is better than many small drug names
How it played out
INVA: thesis partly played out but target was missed
Lyra published INVA at 20.63 on 2025-12-14 with expected growth of 35%. The thesis pointed to FDA approval of a new single-dose oral gonorrhea drug, the planned second-half 2026 sale start, the choice of partner or go-alone commercialization, a recent share drop, and a better mix of business health and price action than many small drug names.
Inside the window, INVA rose to a peak of 25.15 on 2026-02-26, a 21.9% gain. The target was 27.85, and it never got there. The signal ended at 22.03 on 2026-03-14. Verdict: the thesis partly played out, but it missed the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.